725 related articles for article (PubMed ID: 26520418)
21. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.
Kim JH; Shin SH; Kwon HJ; Cho NY; Kang GH
Virchows Arch; 2009 Dec; 455(6):485-94. PubMed ID: 19911194
[TBL] [Abstract][Full Text] [Related]
22. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
23. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.
Bae JM; Kim MJ; Kim JH; Koh JM; Cho NY; Kim TY; Kang GH
Virchows Arch; 2011 Jul; 459(1):55-63. PubMed ID: 21494758
[TBL] [Abstract][Full Text] [Related]
24. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
[TBL] [Abstract][Full Text] [Related]
25. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
[TBL] [Abstract][Full Text] [Related]
27. Left-Sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right-sided ones.
Tanaka J; Watanabe T; Kanazawa T; Tada T; Kazama Y; Tanaka T; Nagawa H
J Surg Oncol; 2007 Dec; 96(7):611-8. PubMed ID: 17786961
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
Bae JM; Kim JH; Kang GH
Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177
[TBL] [Abstract][Full Text] [Related]
29. Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.
Karpinski P; Walter M; Szmida E; Ramsey D; Misiak B; Kozlowska J; Bebenek M; Grzebieniak Z; Blin N; Laczmanski L; Sasiadek MM
Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):201-8. PubMed ID: 23175427
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
[TBL] [Abstract][Full Text] [Related]
31. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
33. Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis.
Zong L; Abe M; Ji J; Zhu WG; Yu D
Clin Transl Gastroenterol; 2016 Mar; 7(3):e151. PubMed ID: 26963001
[TBL] [Abstract][Full Text] [Related]
34. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
[TBL] [Abstract][Full Text] [Related]
36. A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps.
Hokazono K; Ueki T; Nagayoshi K; Nishioka Y; Hatae T; Koga Y; Hirahashi M; Oda Y; Tanaka M
Oncol Lett; 2014 Nov; 8(5):1937-1944. PubMed ID: 25289081
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
38. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases.
Messick CA; Church JM; Liu X; Ting AH; Kalady MF
Ann Surg Oncol; 2010 Feb; 17(2):425-31. PubMed ID: 19885699
[TBL] [Abstract][Full Text] [Related]
39. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
40. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
